SCPH Valuation

scPharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.850

+0.28(6.127%)1D

Overview
Forecast
Valuation
Earnings

SCPH Relative Valuation

SCPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SCPH is overvalued; if below, it's undervalued.

Historical Valuation

scPharmaceuticals Inc (SCPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.35 is considered Undervalued compared with the five-year average of -4.38. The fair price of scPharmaceuticals Inc (SCPH) is between 9.36 to 11.66 according to relative valuation methord. Compared to the current price of 4.81 USD , scPharmaceuticals Inc is Undervalued By 48.61%.

Relative Value

Fair Zone

9.36-11.66

Current Price：4.81

48.61%

Undervalued

-7.38

Trailing

Forward

-8.78

EV/EBITDA

scPharmaceuticals Inc. (SCPH) has a current EV/EBITDA of -8.78. The 5-year average EV/EBITDA is -3.04. The thresholds are as follows: Strongly Undervalued below -6.94, Undervalued between -6.94 and -4.99, Fairly Valued between -1.09 and -4.99, Overvalued between -1.09 and 0.86, and Strongly Overvalued above 0.86. The current Forward EV/EBITDA of -8.78 falls within the Strongly Undervalued range.

-7.93

EV/EBIT

scPharmaceuticals Inc. (SCPH) has a current EV/EBIT of -7.93. The 5-year average EV/EBIT is -3.28. The thresholds are as follows: Strongly Undervalued below -6.33, Undervalued between -6.33 and -4.80, Fairly Valued between -1.75 and -4.80, Overvalued between -1.75 and -0.23, and Strongly Overvalued above -0.23. The current Forward EV/EBIT of -7.93 falls within the Strongly Undervalued range.

2.35

scPharmaceuticals Inc. (SCPH) has a current PS of 2.35. The 5-year average PS is 16.57. The thresholds are as follows: Strongly Undervalued below -33.11, Undervalued between -33.11 and -8.27, Fairly Valued between 41.41 and -8.27, Overvalued between 41.41 and 66.25, and Strongly Overvalued above 66.25. The current Forward PS of 2.35 falls within the Historic Trend Line -Fairly Valued range.

-8.44

P/OCF

scPharmaceuticals Inc. (SCPH) has a current P/OCF of -8.44. The 5-year average P/OCF is -3.89. The thresholds are as follows: Strongly Undervalued below -7.89, Undervalued between -7.89 and -5.89, Fairly Valued between -1.89 and -5.89, Overvalued between -1.89 and 0.12, and Strongly Overvalued above 0.12. The current Forward P/OCF of -8.44 falls within the Strongly Undervalued range.

-8.44

P/FCF

scPharmaceuticals Inc. (SCPH) has a current P/FCF of -8.44. The 5-year average P/FCF is -4.80. The thresholds are as follows: Strongly Undervalued below -9.87, Undervalued between -9.87 and -7.33, Fairly Valued between -2.26 and -7.33, Overvalued between -2.26 and 0.27, and Strongly Overvalued above 0.27. The current Forward P/FCF of -8.44 falls within the Undervalued range.

scPharmaceuticals Inc (SCPH) has a current Price-to-Book (P/B) ratio of -11.13. Compared to its 3-year average P/B ratio of 3.73 , the current P/B ratio is approximately -398.51% higher. Relative to its 5-year average P/B ratio of 3.22, the current P/B ratio is about -445.58% higher. scPharmaceuticals Inc (SCPH) has a Forward Free Cash Flow (FCF) yield of approximately -27.71%. Compared to its 3-year average FCF yield of -28.03%, the current FCF yield is approximately -1.14% lower. Relative to its 5-year average FCF yield of -23.93% , the current FCF yield is about 15.83% lower.

-11.43

P/B

Median3y

3.73

Median5y

3.22

-27.78

FCF Yield

Median3y

-28.03

Median5y

-23.93

Competitors Valuation Multiple

The average P/S ratio for SCPH's competitors is 13.50, providing a benchmark for relative valuation. scPharmaceuticals Inc Corp (SCPH) exhibits a P/S ratio of 2.35, which is -82.61% above the industry average. Given its robust revenue growth of 99.17%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SCPH.O

scPharmaceuticals Inc

Sagimet Biosciences Inc

Aardvark Therapeutics Inc

Loss

211.98M

VNDA.O

Vanda Pharmaceuticals Inc

1.03

4.19%

280.67M

Performance Decomposition

Market capitalization of SCPH decreased by 4.72% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 8.05M to 16.04M.

The secondary factor is the Margin Expansion, contributed -47.05%to the performance.

Overall, the performance of SCPH in the past 1 year is driven by Revenue Growth. Which is more sustainable.

99.17%

8.05M → 16.04M

Revenue Growth

-47.05%

-212.19 → -112.36

Margin Expansion

-56.84%

-5.99 → -2.59

P/E Change

-4.72%